tweenvest

CollPlant Biotechnologies Ltd. (NasdaqCM: OPHI)

Health Care · Biotechnology · IL

$3.60

+9.76% today · -83.3% 1Y

Public summary
A free snapshot of CollPlant Biotechnologies Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

CollPlant Biotechnologies Ltd. (NasdaqCM: OPHI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.81M and employs 39 people.

Over the last twelve months the share price has lost 83.3%, trading between 2.64 and 22.50.

Tweenvest scores CollPlant Biotechnologies Ltd. across four factors: quality 36/100, value 45/100, growth 100/100. Its strongest factor is growth.

OPHI price history

Nov 21, 2025 · 22.20Weekly closes 2.73 – 22.20Nov 17, 2026 · 3.60

Key figures

Market cap
$6.81M
Revenue (TTM)
$318.00K
P/E
-0.54
EPS
-9.38
Dividend yield
—
Beta (5Y)
0.57
52-week high
$22.50
52-week low
$2.64
Avg volume (3M)
—
Shares outstanding
1.89M
Employees
39
Next earnings
—

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.

ISIN
IL0004960188
Founded
2004
Listed since
Jan 31, 2018
Exchange
Nasdaq Capital Market
Currency
USD
CompanyMarket capPriceDay
Hemostemix Inc.TSXV: HEM$7.42MCA$0.050.00%
Arctic Bioscience ASOB: ABS$7.16MNkr2.54+3.67%
Delta-Fly Pharma, Inc.TSE: 4598$7.01M¥58.00+1.75%
Exicure, Inc.NasdaqCM: XCUR$7.00M$1.07-0.93%
Marvel Biosciences Corp.TSXV: MRVL$6.73MCA$0.13+4.00%
GT Biopharma, Inc.NasdaqCM: GTBP$6.71M$3.72-3.12%
Theriva Biologics, Inc.NYSEAM: TOVX$6.61M$0.14+2.86%
Moleculin Biotech, Inc.NasdaqCM: MBRX$6.57M$6.75-1.17%

Browse every Biotechnology company →